USPTO Director Overturns PTAB Decision, Rekindling Hormonal Disorder Treatment Innovation

In a recent development, the director of the U.S. Patent and Trademark Office (USPTO) has overturned a Patent Trial and Appeal Board (PTAB) decision that declined to re-evaluate a biotech firm’s patent pertaining to a hormonal disorder treatment. The reversal came on Friday, and it was a significant move by Andrei Iancu, the USPTO Director….

Read More

PTAB Emphasizes Degree of Investment in Parallel Proceedings for Fintiv Factor 3 Decision

In a relevant recent development, the PTAB (Patent Trial and Appeal Board) granted the institution of an Inter Partes Review (IPR) in light of several parallel district court proceedings regarding the same patent. The Board was not persuaded by the Patent Owner’s argument that the petitioner’s “conflicting” stances regarding claim construction within the district court…

Read More

AI and IP: Navigating the Complex Intersection of Artificial Intelligence and Intellectual Property Rights

Artificial Intelligence (AI) tools, ranging from text and image generators to music and software code marvelling utilities, have seen a significant proliferation recently. However, their integration with Intellectual Property (IP) has been the subject of intense discussion in legal circles. One of the key focal points of these debates circles around whether works of art…

Read More

Apple and Samsung Patent Lawsuits Highlight Jurisdictional Discrepancy in Texas Court

In a recent patent lawsuit involving technology giant Apple and its South Korean competitor Samsung, Western District of Texas Judge Alan Albright demonstrated a contrasting decision in the courtroom. Significant to the legal professionals and corporations worldwide, this occurrence casts useful insights into the current justice system’s decision-making process with respect to patent suits. Apple…

Read More

Bankrupt Automaker Lordstown Motors Attracts 13 Potential Bidders Amid IP Battle

Lordstown Motors, the bankrupt electric automaker, revealed to a Delaware judge that it had received expressions of interest from 13 potential bidders as part of its Chapter 11 sale process. Despite a forthcoming trial over trade secret claims, which has undoubtedly caused estrangement amongst some potential suitors, the judge approved the majority of Lordstown’s proposed…

Read More

PacBio Patent Infringement Case Transferred from Delaware to California

The patent infringement case against biotechnology firm Pacific Biosciences of California Inc. has been moved from a Delaware federal court to California. According to the judgement, there were insufficient reasons to support maintaining the case proceedings in Delaware. Pacific Biosciences of California Inc., commonly known as PacBio, is a biotechnology company that’s profusely involved in…

Read More

Federal Circuit Delivers Pivotal Ruling in United Therapeutics v. Liquidia Pharmaceuticals Patent Case

In the continually evolving arena of patent law, the third week of July 2023 has seen pivotal advancement in patent cases adjudicated by the Federal Circuit. One such central case involved the United Therapeutics Corp. and Liquidia Technologies, Inc. (Nos. 2022-2217, 2023-1021, Fed. Cir. (D. Del.) July 24, 2023). The case merits attention due to…

Read More

Navigating Complexities: Federal Circuit Overturns Board Decision on Sanofi-Aventis Patent

The Federal Circuit recently overturned a Patent Trial and Appeal Board (“Board”) decision, which had declared certain claims of Sanofi-Aventis’ ‘614 patent as evidently unpatentable. This significant move indicates the ongoing dynamism and challenges surrounding legal decision-making in the world of intellectual property. [Read more here.] The patent under examination was owned by Sanofi-Aventis Deutschlan…

Read More

Amid Competency Investigation, Judge Newman Challenges Patent Eligibility Law

Legal professionals worldwide must keep an attentive eye on the ongoing saga of 96-year-old Federal Circuit Judge, Pauline Newman. Currently subjected to a competency investigation, Judge Newman made headlines once again as she openly criticized the current patent eligibility law as “unnecessary and confusing” while raising questions about its divergence from its “historical purpose”. In…

Read More

Court Ruling Bolsters Patent Protection for “Therapeutically Effective” Dose Claims in Medical Treatments

In a recent ruling by the U.S. Court of Appeals for the Federal Circuit, it has been determined that a claim to a treatment method for pulmonary hypertension cannot be invalidated for lacking enablement or written description. The case at hand is United Therapeutics Corporation v. Liquidia Technologies, Inc. The court declared that the claims,…

Read More

US Patent & Trademark Office Announces Major Procedural Changes, Impacting AIA Proceedings and Patent Disputes

On July 24, 2023, the US Patent & Trademark Office (PTO) announced some notable changes in its review procedures, specifically in the interim Director Review (DR) process and Appeals Review Panel (ARP) process. These changes mark the end of the Precedential Opinion Panel Process, which was previously in place. One significant update to the interim…

Read More